These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 22001270)

  • 1. Identification of hepatitis B virus rtS117F substitution as a compensatory mutation for rtM204I during lamivudine therapy.
    Lin CL; Chien RN; Hu CC; Lai MW; Yeh CT
    J Antimicrob Chemother; 2012 Jan; 67(1):39-48. PubMed ID: 22001270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B.
    Coppola N; Tonziello G; Colombatto P; Pisaturo M; Messina V; Moriconi F; Alessio L; Sagnelli C; Cavallone D; Brunetto M; Sagnelli E
    J Infect; 2013 Oct; 67(4):322-8. PubMed ID: 23796869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation.
    Ji D; Liu Y; Li L; Xu Z; Si LL; Dai JZ; Li X; Wang L; Yao Z; Xin SJ; Chen GF; Xu D
    J Clin Virol; 2012 May; 54(1):66-72. PubMed ID: 22398037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and chronicity of acute hepatitis B induced by lamivudine-resistant strains.
    Luo Q; Zhong Y; Yang Y; Xiong Q; Hu Z; Lu W; Huang P; Zhang N
    J Med Virol; 2012 Oct; 84(10):1558-61. PubMed ID: 22930503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute hepatitis B infection associated with drug-resistant hepatitis B virus.
    Xu Z; Liu Y; Xu T; Chen L; Si L; Wang Y; Ren X; Zhong Y; Zhao J; Xu D
    J Clin Virol; 2010 Aug; 48(4):270-4. PubMed ID: 20580309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent detection of hepatitis B virus variants associated with lamivudine resistance in treated South African patients infected chronically with different HBV genotypes.
    Selabe SG; Song E; Burnett RJ; Mphahlele MJ
    J Med Virol; 2009 Jun; 81(6):996-1001. PubMed ID: 19382250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
    Ohkawa K; Takehara T; Kato M; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
    J Infect Dis; 2008 Oct; 198(8):1150-8. PubMed ID: 18713056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
    Suzuki F; Akuta N; Suzuki Y; Sezaki H; Arase Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Watahiki S; Kumada H
    J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern.
    Damerow H; Yuen L; Wiegand J; Walker C; Bock CT; Locarnini S; Tillmann HL
    J Med Virol; 2010 Nov; 82(11):1850-8. PubMed ID: 20872711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
    Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
    J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region.
    Natsuizaka M; Hige S; Ono Y; Ogawa K; Nakanishi M; Chuma M; Yoshida S; Asaka M
    J Viral Hepat; 2005 Mar; 12(2):154-9. PubMed ID: 15720530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of peptide nucleic acid mediated polymerase chain reaction clamping (PMPC)--direct sequencing method for detecting lamivudine-resistant hepatitis B virus (HBV) variants with high sensitivity and specificity.
    Ogata N; Ichida T; Aoyagi Y; Kitajima I
    Rinsho Byori; 2003 Apr; 51(4):313-9. PubMed ID: 12747252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.
    Zhu Y; Curtis M; Borroto-Esoda K
    Antivir Chem Chemother; 2011 Aug; 22(1):13-22. PubMed ID: 21860069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High frequency of complex mutational patterns in lamivudine resistant hepatitis B virus isolates.
    Neumann-Fraune M; Beggel B; Pfister H; Kaiser R; Verheyen J
    J Med Virol; 2013 May; 85(5):775-9. PubMed ID: 23408582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy.
    Yeh CT; Chien RN; Chu CM; Liaw YF
    Hepatology; 2000 Jun; 31(6):1318-26. PubMed ID: 10827158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of multi-drug resistant hepatitis B virus during sequential therapy.
    Yim HJ; Hussain M; Liu Y; Wong SN; Fung SK; Lok AS
    Hepatology; 2006 Sep; 44(3):703-12. PubMed ID: 16941700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.
    Chayama K; Suzuki Y; Kobayashi M; Kobayashi M; Tsubota A; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Murashima N; Ikeda K; Kumada H
    Hepatology; 1998 Jun; 27(6):1711-6. PubMed ID: 9620347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B.
    Iacomi F; Vincenti D; Vairo F; Solmone M; Mariano A; Piselli P; Puro V; Capobianchi MR; Antonucci G
    J Med Virol; 2009 Jul; 81(7):1151-6. PubMed ID: 19475624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and virological effects of long-term (over 5 years) lamivudine therapy.
    Hashimoto Y; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saito S; Suzuki Y; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2010 Apr; 82(4):684-91. PubMed ID: 20166170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.